Rilpivirine: Difference between revisions
m (Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +)) |
Gerald Chi (talk | contribs) m (Changed protection level for "Rilpivirine" ([Edit=Allow only autoconfirmed users] (expires 14:49, 16 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 14:49, 16 January 2014 (UTC)))) |
(No difference)
| |
Revision as of 14:49, 2 January 2014
{{Drugbox
| IUPAC_name = 4-{[4-({4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl}
amino)pyrimidin-2-yl]amino}benzonitrile
| image = Rilpivirine.svg
| CAS_number = 500287-72-9
| ATC_prefix =
| ATC_suffix =
| PubChem = 6451164
| DrugBank =
| C=22|H=18|N=6
| molecular_weight = 366.42 g/mol
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life = 38 hours
| excretion =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category=
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration = Oral
}}
Rilpivirine (TMC278) is a diarylpyrimidine under under investigation as a treatment for HIV infection. It is a non-nucleoside reverse transcriptase inhibitor with many times the potency of current available agents in that class, such as efavirenz.[1][2]It is expected to be FDA approved as soon as 2009.[3]
References
- ↑ Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, de Béthune MP, Peeters M, Woodfall B (2006). "Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects". AIDS. 20 (13): 1721–6. doi:10.1097/01.aids.0000242818.65215.bd. PMID 16931936.
- ↑ Pozniak A, Morales-Ramirez J, Mohap L et al. 48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients. Oral abstract 144LB.
- ↑ Steve Mitchell. HIV Market To Top 10 Billion Dollars. United Press International. April 11, 2007.